Phytonix’s CEO presented and participated in a panel discussion at a high-profile study on “Future Biotechnology Products and Opportunities to Enhance Capabilities of the Biotechnology Regulatory System” at the request of the U.S. EPA, USDA, FDA and the White House Office of Science and Technology Policy on June 27th, 2016 in San Francisco USA
Mr. Bruce Dannenberg, President and CEO of Phytonix Corporation, accepted an invitation to participate in and present at the one-day information-gathering meeting organized by The National Academies of Sciences, Engineering, and Medicine to answer the questions “What will the likely future products of biotechnology be over the next 5-10 years? What scientific capabilities, tools, and/or expertise may be needed by the regulatory agencies to ensure they make efficient and sound evaluations of the likely future products of biotechnology?”
Mr. Dannenberg provided the committee with important and valuable insights in regards to Phytonix’s breakthrough technology and it’s leadership approach for the utilization of both passive and active (proprietary) strategies and technology for the bio-safety guarded photobiological production of sustainable chemicals. This could provide a framework for future self-regulatory approaches and how these types of approaches might relate to appropriate future levels of mandated regulations.
To view Mr. Dannenberg’s presentation click the link below.